Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging

Youssef Zaim Wadghiri, Einar M. Sigurdsson, Marcin Sadowski, James I. Elliott, Yongsheng Li, Henrieta Scholtzova, Cheuk Ying Tang, Gilbert Aguinaldo, Miguel Pappolla, Karen Duff, Thomas Wisniewski, Daniel H. Turnbull

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

The presence of amyloid-β (Aβ) plaques in the brain is a hallmark pathological feature of Alzheimer's disease (AD). Transgenic mice overexpressing mutant amyloid precursor protein (APP), or both mutant APP and presenilin-1 (APP/PS1), develop Aβ plaques similar to those in AD patients, and have been proposed as animal models in which to test experimental therapeutic approaches for the clearance of Aβ. However, at present there is no in vivo wholebrain imaging method to detect Aβ plaques in mice or men. A novel method is presented to detect Aβ plaques in the brains of transgenic mice by magnetic resonance microimaging (μMRI). This method uses Aβ1-40 peptide, known for its high binding affinity to Aβ, magnetically labeled with either gadolinium (Gd) or monocrystalline iron oxide nanoparticles (MION). Intraarterial injection of magnetically labeled Aβ1-40, with mannitol to transiently open the blood-brain barrier (BBB), enabled the detection of many Aβ plaques. Furthermore, the numerical density of Aβ plaques detected by μMRI and by immunohistochemistry showed excellent correlation. This approach provides an in vivo method to detect Aβ in AD transgenic mice, and suggests that diagnostic MRI methods to detect Aβ in AD patients may ultimately be feasible.

Original languageEnglish (US)
Pages (from-to)293-302
Number of pages10
JournalMagnetic Resonance in Medicine
Volume50
Issue number2
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Amyloid
Transgenic Mice
Magnetic Resonance Spectroscopy
Alzheimer Disease
Mutant Proteins
Presenilin-1
Intra-Arterial Injections
Amyloid Plaques
Gadolinium
Brain
Mannitol
Blood-Brain Barrier
Animal Models
Immunohistochemistry
Peptides
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Wadghiri, Y. Z., Sigurdsson, E. M., Sadowski, M., Elliott, J. I., Li, Y., Scholtzova, H., ... Turnbull, D. H. (2003). Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magnetic Resonance in Medicine, 50(2), 293-302. https://doi.org/10.1002/mrm.10529

Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. / Wadghiri, Youssef Zaim; Sigurdsson, Einar M.; Sadowski, Marcin; Elliott, James I.; Li, Yongsheng; Scholtzova, Henrieta; Tang, Cheuk Ying; Aguinaldo, Gilbert; Pappolla, Miguel; Duff, Karen; Wisniewski, Thomas; Turnbull, Daniel H.

In: Magnetic Resonance in Medicine, Vol. 50, No. 2, 01.08.2003, p. 293-302.

Research output: Contribution to journalArticle

Wadghiri, YZ, Sigurdsson, EM, Sadowski, M, Elliott, JI, Li, Y, Scholtzova, H, Tang, CY, Aguinaldo, G, Pappolla, M, Duff, K, Wisniewski, T & Turnbull, DH 2003, 'Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging', Magnetic Resonance in Medicine, vol. 50, no. 2, pp. 293-302. https://doi.org/10.1002/mrm.10529
Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H et al. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magnetic Resonance in Medicine. 2003 Aug 1;50(2):293-302. https://doi.org/10.1002/mrm.10529
Wadghiri, Youssef Zaim ; Sigurdsson, Einar M. ; Sadowski, Marcin ; Elliott, James I. ; Li, Yongsheng ; Scholtzova, Henrieta ; Tang, Cheuk Ying ; Aguinaldo, Gilbert ; Pappolla, Miguel ; Duff, Karen ; Wisniewski, Thomas ; Turnbull, Daniel H. / Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. In: Magnetic Resonance in Medicine. 2003 ; Vol. 50, No. 2. pp. 293-302.
@article{0f336e09dc394d21ba5767d8bbab756d,
title = "Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging",
abstract = "The presence of amyloid-β (Aβ) plaques in the brain is a hallmark pathological feature of Alzheimer's disease (AD). Transgenic mice overexpressing mutant amyloid precursor protein (APP), or both mutant APP and presenilin-1 (APP/PS1), develop Aβ plaques similar to those in AD patients, and have been proposed as animal models in which to test experimental therapeutic approaches for the clearance of Aβ. However, at present there is no in vivo wholebrain imaging method to detect Aβ plaques in mice or men. A novel method is presented to detect Aβ plaques in the brains of transgenic mice by magnetic resonance microimaging (μMRI). This method uses Aβ1-40 peptide, known for its high binding affinity to Aβ, magnetically labeled with either gadolinium (Gd) or monocrystalline iron oxide nanoparticles (MION). Intraarterial injection of magnetically labeled Aβ1-40, with mannitol to transiently open the blood-brain barrier (BBB), enabled the detection of many Aβ plaques. Furthermore, the numerical density of Aβ plaques detected by μMRI and by immunohistochemistry showed excellent correlation. This approach provides an in vivo method to detect Aβ in AD transgenic mice, and suggests that diagnostic MRI methods to detect Aβ in AD patients may ultimately be feasible.",
author = "Wadghiri, {Youssef Zaim} and Sigurdsson, {Einar M.} and Marcin Sadowski and Elliott, {James I.} and Yongsheng Li and Henrieta Scholtzova and Tang, {Cheuk Ying} and Gilbert Aguinaldo and Miguel Pappolla and Karen Duff and Thomas Wisniewski and Turnbull, {Daniel H.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1002/mrm.10529",
language = "English (US)",
volume = "50",
pages = "293--302",
journal = "Magnetic Resonance in Medicine",
issn = "0740-3194",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging

AU - Wadghiri, Youssef Zaim

AU - Sigurdsson, Einar M.

AU - Sadowski, Marcin

AU - Elliott, James I.

AU - Li, Yongsheng

AU - Scholtzova, Henrieta

AU - Tang, Cheuk Ying

AU - Aguinaldo, Gilbert

AU - Pappolla, Miguel

AU - Duff, Karen

AU - Wisniewski, Thomas

AU - Turnbull, Daniel H.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - The presence of amyloid-β (Aβ) plaques in the brain is a hallmark pathological feature of Alzheimer's disease (AD). Transgenic mice overexpressing mutant amyloid precursor protein (APP), or both mutant APP and presenilin-1 (APP/PS1), develop Aβ plaques similar to those in AD patients, and have been proposed as animal models in which to test experimental therapeutic approaches for the clearance of Aβ. However, at present there is no in vivo wholebrain imaging method to detect Aβ plaques in mice or men. A novel method is presented to detect Aβ plaques in the brains of transgenic mice by magnetic resonance microimaging (μMRI). This method uses Aβ1-40 peptide, known for its high binding affinity to Aβ, magnetically labeled with either gadolinium (Gd) or monocrystalline iron oxide nanoparticles (MION). Intraarterial injection of magnetically labeled Aβ1-40, with mannitol to transiently open the blood-brain barrier (BBB), enabled the detection of many Aβ plaques. Furthermore, the numerical density of Aβ plaques detected by μMRI and by immunohistochemistry showed excellent correlation. This approach provides an in vivo method to detect Aβ in AD transgenic mice, and suggests that diagnostic MRI methods to detect Aβ in AD patients may ultimately be feasible.

AB - The presence of amyloid-β (Aβ) plaques in the brain is a hallmark pathological feature of Alzheimer's disease (AD). Transgenic mice overexpressing mutant amyloid precursor protein (APP), or both mutant APP and presenilin-1 (APP/PS1), develop Aβ plaques similar to those in AD patients, and have been proposed as animal models in which to test experimental therapeutic approaches for the clearance of Aβ. However, at present there is no in vivo wholebrain imaging method to detect Aβ plaques in mice or men. A novel method is presented to detect Aβ plaques in the brains of transgenic mice by magnetic resonance microimaging (μMRI). This method uses Aβ1-40 peptide, known for its high binding affinity to Aβ, magnetically labeled with either gadolinium (Gd) or monocrystalline iron oxide nanoparticles (MION). Intraarterial injection of magnetically labeled Aβ1-40, with mannitol to transiently open the blood-brain barrier (BBB), enabled the detection of many Aβ plaques. Furthermore, the numerical density of Aβ plaques detected by μMRI and by immunohistochemistry showed excellent correlation. This approach provides an in vivo method to detect Aβ in AD transgenic mice, and suggests that diagnostic MRI methods to detect Aβ in AD patients may ultimately be feasible.

UR - http://www.scopus.com/inward/record.url?scp=0038637737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038637737&partnerID=8YFLogxK

U2 - 10.1002/mrm.10529

DO - 10.1002/mrm.10529

M3 - Article

C2 - 12876705

AN - SCOPUS:0038637737

VL - 50

SP - 293

EP - 302

JO - Magnetic Resonance in Medicine

JF - Magnetic Resonance in Medicine

SN - 0740-3194

IS - 2

ER -